We conducted a case-control study to measure the risk of pulmonary side effects following
the use of topical glaucoma medications, particularly the [beta] blockers, and to identify …

Glaucoma, a disease that affects between 1 and 3% of the population above the age of 60,
is most commonly treated by topical beta‐adrenergic blockers. Although effective in lowering …

Background/aims: Topical β antagonists are prescribed for glaucoma in approximately 500
000 people in the United Kingdom. The authors have previously shown that topical β …

Early clinical studies revealed that timolol and other topical β blockers were effective in
reducing intra‐ocular pressure, without the side effects associated with other antiglaucoma …

Although topical [beta]-blockers are generally tolerated, they can produce significant
systemic side effects. The systemic side effects of nonselective [beta]-blockers (eg, timolol …

The success of medical treatment for the management of glaucoma depends largely on
patients' compliance with the treatment regimen. Ophthalmic topical beta blockers have had …

Abstract Background: In Canada, public drug plans may restrict the use of newer topical
antiglaucoma agents. The goals of this retrospective study were to estimate the proportion of …

Objective To assess the impact of long-term treatment with topical timolol on bronchial
reactivity in healthy individuals. Methods Twenty-one otherwise healthy individuals with high …

AIM To investigate respiratory and cardiovascular side effects in elderly people in the first 12
months after commencing topical β antagonists. METHODS 40 patients (mean age 74 years) …

Purpose: To investigate the use of topical ocular anti-glaucoma medications by
glaucomatous patients with obstructive pulmonary disease and their effect on related …